出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年10月
Cardiac Marker Testing Market – Global Forecast to 2028
心臓マーカー検査市場 : バイオマーカー (トロポニン、CK-MB、BNP、hs-CRP、ミオグロビン)、製品 [機器 (化学発光、ELISA)、試薬＆キット]、疾患 (MI、CHF、アテローム性動脈硬化)、ユーザー、ASP 、購入基準 – 2028年までの世界予測
Cardiac Marker Testing Market by Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Product (Instrument (Chemiluminescence, ELISA), Reagents & Kits), Disease (MI, CHF, Atherosclerosis), User, ASP & Buying Criteria – Global Forecast to 2028
| ページ数 | 216 |
| 図表数 | 176 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The global cardiac marker testing market is projected to reach USD 6.9 billion by 2028 from USD 4.1 billion in 2022, growing at a CAGR of 9.4% during the forecast period. The projected surge in market growth for cardiac marker testing is underpinned by a confluence of compelling advantages. Notably, cardiac marker testing is driven by aging population, rising cases of cardiovascular diseases, increase in research & funding initiatives from public/private organizations to discover novel cardiac biomarkers. Furthermore, the escalating early detection of heart failure diseases with improved efficacy for diagnosing heart conditions amplifies the demand for advanced treatment modalities, with cardiac marker testing positioned as a forefront solution. This convergence of factors is poised to usher in a phase of robust expansion within the market, consequently shaping the landscape of cardiac marker testing adoption in the forthcoming forecasting years.
“Troponin I and T segment to register largest market share in 2022-2028”
Based on the biomarker type, cardiac marker testing market is segmented into Troponin I and T, Creatine Kinase-MB (CK-MB), Brain Natriuretic Peptide (BNP and NT-PROBNP), Myoglobin, High-sensitivity C-reactive Protein (hs-CRP), and other cardiac biomarkers. The Troponin I and T segment register a largest market share over the forecast period of 2022-2028. The growth of this segment is propelled by factors such as exceptional sensitivity and specificity, prolonged elevation duration (with levels rising over 4-8 hours, peaking at 10-24 hours, and declining over ten days), and the swift prediction of outcomes. Moreover, lab technicians are more adept at utilizing these markers in comparison to other biomarkers, further fueling the segment’s advancement.
“Laboratory testing facilities segment held the largest share of cardiac marker testing market in 2022, by End-user.”
Based on the end-user, the cardiac marker testing market is segmented into laboratory testing facilities, academic institutes, and point-of-care testing facilities. In 2022, the laboratory testing facilities segment accounted for the largest share of 61.2% of the global cardiac marker testing market. The growth of this segment is being propelled by factors including increased testing efficiency, superior sensitivity and diagnostic precision in comparison to point-of-care testing, and a strong preference for laboratory testing over point-of-care testing.
“Asia Pacific to register significant growth rate in the market during the forecast period.”
For the forecasting period 2023-2028, the APAC region is expected to register a significant growth rate in the market during the forecast period. Asia Pacific comprises India, China, Japan, Australia, South Korea, and RoAPAC. The Asia-Pacific (APAC) region has witnessed a significant increase in the market growth rate for cardiac marker testing. There are several drivers that contributed to this growth:
The Asia Pacific market is experiencing growth due to increased investments by government agencies in emerging countries, aimed at enhancing healthcare infrastructure. Additionally, the market is benefiting from the rise in independent clinical laboratories, a substantial patient population, and strategic initiatives by industry players to expand their offerings of cardiac testing products in the Asia Pacific region.
A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–43%, Tier 2–30%, and Tier 3– 27%
• By Designation: C-level–10%, Director-level–15%, and Others–75%
• By Region: North America–40%, Europe–30%, Asia Pacific–23%, Latin America–5%, and the Middle East & Africa–2%
Prominent players in this market are F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), ), Thermo Fisher Scientific Inc. (US) among others.
Research Coverage
• The report studies the marker testing market based on products, biomarker type, diseases, end user, and region.
• The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
• The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
• The report studies micro markets with respect to their growth trends, prospects, and contributions to the global cardiac marker testing market
• The report forecasts the revenue of market segments with respect to five major regions.
Key Benefits of Buying the Report:
The report will help the new entrants/ market leaders/smaller firms in this market with investment evaluation viability within the cardiac marker testing market through a thorough analysis of comprehensive data, thereby facilitating robust risk assessment and enabling well-informed investment determinations. Benefit from meticulous market segmentation encompassing application, end-user, and regional dimensions, affording tailored insights for precise segment targeting. The report also provides an all-encompassing evaluation of encapsulating pivotal trends, challenges, growth catalysts and prospects, thereby empowering strategic decision-making with astute discernment.
The report provides insights on the following pointers:
• Analysis of key drivers (increasing prevalence of cardiovascular diseases, Increasing geriatric population and subsequent rise in heart conditions worldwide, Ongoing clinical trials for the identification of novel cardiac biomarkers), restraints (Technical issues related to sample collection & storage, Unfavorable regulatory processes and limited reimbursement structure), opportunities (Point-of-care testing (POCT) with cardiac biomarkers, Emerging markets offers high-growth opportunities, Ongoing research on novel cardiac biomarkers for cardiovascular diseases), and challenges (Challenges associated with biomarker assay validation) influencing the growth of the cardiac marker testing market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the cardiac marker testing market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the cardiac marker testing market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cardiac marker testing market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like F.Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), among others.
Table of Contents
1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY 29
1.3 MARKET SCOPE 29
1.3.1 MARKETS COVERED 29
1.3.2 REGIONS COVERED 30
1.4 YEARS CONSIDERED 30
1.5 CURRENCY 31
1.6 RESEARCH LIMITATIONS 31
1.7 MARKET STAKEHOLDERS 31
1.8 SUMMARY OF CHANGES 31
1.8.1 RECESSION IMPACT 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
2.2 RESEARCH DESIGN 34
2.2.1 SECONDARY RESEARCH 34
FIGURE 1 KEY DATA FROM SECONDARY SOURCES 36
2.2.2 PRIMARY RESEARCH 36
2.2.2.1 Primary sources 37
2.2.2.2 Key industry insights 38
2.2.2.3 Breakdown of primaries 38
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 38
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 39
2.3 MARKET SIZE ESTIMATION 39
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 40
2.3.1 BOTTOM-UP APPROACH 41
2.3.2 APPROACH 1: COMPANY REVENUE ESTIMATION APPROACH 41
FIGURE 5 CARDIAC MARKER TESTING MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION) 41
2.3.3 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION 42
FIGURE 6 CARDIAC MARKER TESTING MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 42
2.3.4 APPROACH 3: TOP-DOWN APPROACH 43
2.3.5 APPROACH 4: PRIMARY INTERVIEWS 43
FIGURE 7 CARDIAC MARKER TESTING MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 43
2.4 DATA TRIANGULATION AND MARKET BREAKDOWN 44
FIGURE 8 DATA TRIANGULATION METHODOLOGY 45
2.5 MARKET SHARE ASSESSMENT 46
2.6 STUDY ASSUMPTIONS 46
2.7 RISK ASSESSMENT 46
TABLE 1 LIMITATIONS AND ASSOCIATED RISKS 46
2.8 GROWTH RATE ASSUMPTIONS 47
2.9 RECESSION IMPACT 47
3 EXECUTIVE SUMMARY 48
FIGURE 9 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2023 VS. 2028 (USD MILLION) 48
FIGURE 10 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 49
FIGURE 11 CARDIAC MARKER TESTING MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION) 49
FIGURE 12 CARDIAC MARKER TESTING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 50
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF CARDIAC MARKER TESTING MARKET 51
4 PREMIUM INSIGHTS 52
4.1 CARDIAC MARKER TESTING MARKET OVERVIEW 52
FIGURE 14 RISING PREVALENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET 52
4.2 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY AND END USER, 2022 53
FIGURE 15 LABORATORY TESTING FACILITIES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022 53
4.3 CARDIAC MARKER TESTING MARKET: REGIONAL MIX 54
FIGURE 16 NORTH AMERICA WILL CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD 54
4.4 CARDIAC MARKER TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 55
FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
FIGURE 18 CARDIAC MARKER TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
5.1.1 DRIVERS 57
5.1.1.1 Rising prevalence of cardiovascular diseases 57
5.1.1.2 Increasing geriatric population and subsequent rise in heart conditions worldwide 57
5.1.1.3 Growing research and funding initiatives from public and private organizations 58
5.1.1.4 Rising clinical studies for identification of novel cardiac biomarkers 58
5.1.2 RESTRAINTS 58
5.1.2.1 Technical issues related to sample collection and storage 58
5.1.2.2 Unfavorable regulatory processes and limited reimbursement structure 59
5.1.3 OPPORTUNITIES 60
5.1.3.1 Point-of-care testing with cardiac biomarkers 60
5.1.3.2 Ongoing research on novel cardiac biomarkers for cardiovascular diseases 60
5.1.3.3 Emerging markets 61
5.1.4 CHALLENGES 61
5.1.4.1 Challenges associated with biomarker assay validation 61
5.2 KEY STAKEHOLDERS AND BUYING CRITERIA 62
5.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 62
FIGURE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CARDIAC MARKER TESTING MARKET 62
TABLE 2 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR KEY PRODUCT SEGMENTS (%) 62
5.3 PORTER’S FIVE FORCES ANALYSIS 62
TABLE 3 CARDIAC MARKER TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 63
5.3.1 THREAT OF NEW ENTRANTS 63
5.3.2 THREAT OF SUBSTITUTES 63
5.3.3 BARGAINING POWER OF SUPPLIERS 63
5.3.4 BARGAINING POWER OF BUYERS 63
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 64
5.4 REGULATORY ANALYSIS 64
5.4.1 US 64
TABLE 4 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 65
5.4.2 EUROPE 65
TABLE 5 EUROPE: CLASSIFICATION OF IVD DEVICES 65
5.4.3 JAPAN 66
TABLE 6 JAPAN: CLASSIFICATION OF IVD REAGENTS 66
TABLE 7 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 66
5.5 REIMBURSEMENT SCENARIO 66
TABLE 8 REIMBURSEMENT CODES FOR VARIOUS BIOMARKERS 67
5.6 ECOSYSTEM MAPPING 68
5.7 VALUE CHAIN ANALYSIS 68
5.7.1 RESEARCH & DEVELOPMENT 68
5.7.2 PROCUREMENT AND PRODUCT DEVELOPMENT 68
5.7.3 MARKETING, SALES AND DISTRIBUTION, AND POST-SALES SERVICES 68
FIGURE 20 VALUE CHAIN ANALYSIS OF CARDIAC MARKER TESTING MARKET 69
5.8 SUPPLY CHAIN ANALYSIS 69
5.8.1 PROMINENT COMPANIES 69
5.8.2 SMALL & MEDIUM-SIZED COMPANIES 69
5.8.3 END USERS 69
FIGURE 21 SUPPLY CHAIN ANALYSIS OF CARDIAC MARKER TESTING MARKET 70
5.9 PRICING ANALYSIS 70
TABLE 9 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER TROPONIN I AND T TEST KITS, 2021 70
TABLE 10 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER BPN AND NT-PROBNP TEST KITS, 2021 71
TABLE 11 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER MYOGLOBIN TEST KITS, 2021 71
TABLE 12 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER CK-MB TEST KITS, 2022 71
TABLE 13 AVERAGE SELLING PRICE OF CARDIAC BIOMARKER C-REACTIVE PROTEIN (HS-CRP) TEST KITS, 2022 71
TABLE 14 AVERAGE SELLING PRICE TREND OF CARDIAC MARKER TEST KITS, BY COUNTRY, 2021–2023 (USD) 72
5.10 PATENT ANALYSIS 72
FIGURE 22 TOP 10 PATENT APPLICANTS FOR CARDIAC MARKER TESTING, JANUARY 2012–SEPTEMBER 2022 73
FIGURE 23 TOP 10 PATENT OWNERS FOR CARDIAC MARKER TESTING, JANUARY 2012–SEPTEMBER 2022 73
5.11 TRADE ANALYSIS 73
TABLE 15 IMPORT DATA FOR CARDIAC MARKER TESTING (HS CODE 3822), BY COUNTRY, 2018–2022 (USD THOUSAND) 74
TABLE 16 EXPORT DATA FOR CARDIAC MARKER TESTING (HS CODE 3822), BY COUNTRY, 2018–2022 (USD THOUSAND) 74
5.12 CASE STUDIES 75
TABLE 17 CASE STUDY: BREAKTHROUGH IN ACUTE MYOCARDIAL INFARCTION DIAGNOSIS WITH HIGH-SENSITIVITY TROPONIN I ASSAYS 75
5.13 KEY CONFERENCES AND EVENTS, 2023–2024 75
TABLE 18 CARDIAC MARKER TESTING MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS IN 2023–2024 75
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 76
FIGURE 24 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX 76
5.15 IMPACT OF RECESSION ON CARDIAC MARKER TESTING MARKET 76
6 CARDIAC MARKER TESTING MARKET, BY PRODUCT 78
6.1 INTRODUCTION 79
TABLE 19 CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 79
6.2 REAGENTS & KITS 79
6.2.1 RISING VOLUME OF DIAGNOSTIC TESTS TO DRIVE DEMAND 79
TABLE 20 CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 80
TABLE 21 CARDIAC MARKER TESTING REAGENTS & KITS MARKET, BY REGION, 2021–2028 (USD MILLION) 80
6.3 INSTRUMENTS 81
TABLE 22 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 81
TABLE 23 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 81
TABLE 24 CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 82
6.3.1 CHEMILUMINESCENCE 82
6.3.1.1 Most preferred method for quantifying cardiac biomarkers 82
TABLE 25 CHEMILUMINESCENCE INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 83
TABLE 26 CHEMILUMINESCENCE INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 83
6.3.2 IMMUNOFLUORESCENCE 84
6.3.2.1 Demand for stable and safer reagents to support market growth 84
TABLE 27 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 84
TABLE 28 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 85
6.3.3 ELISA 85
6.3.3.1 Long shelf life and ease of use to propel growth 85
TABLE 29 ELISA INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 85
TABLE 30 ELISA INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 86
6.3.4 IMMUNOCHROMATOGRAPHY 86
6.3.4.1 Increasing use in point-of-care settings to propel adoption 86
TABLE 31 IMMUNOCHROMATOGRAPHY INSTRUMENTS MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 87
TABLE 32 IMMUNOCHROMATOGRAPHY INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 87
7 CARDIAC MARKER TESTING MARKET, BY INDICATION 88
7.1 INTRODUCTION 89
TABLE 33 CARDIAC MARKER TESTING MARKET, BY INDICATION, 2021–2028 (USD MILLION) 89
7.2 MYOCARDIAL INFARCTION 89
7.2.1 AVAILABILITY OF HIGH-SENSITIVITY BIOMARKERS FOR DETECTION TO DRIVE MARKET 89
TABLE 34 CARDIAC MARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2021–2028 (USD MILLION) 90
7.3 CONGESTIVE HEART FAILURE 90
7.3.1 INCREASING USE OF MULTIMARKER TESTING TO SUPPORT MARKET GROWTH 90
TABLE 35 CARDIAC MARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2021–2028 (USD MILLION) 91
7.4 ACUTE CORONARY SYNDROME 91
7.4.1 INCREASING INCIDENCE OF RISK FACTORS ASSOCIATED WITH ACS TO DRIVE ADOPTION OF CARDIAC MARKERS 91
TABLE 36 CARDIAC MARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2021–2028 (USD MILLION) 92
7.5 ATHEROSCLEROSIS 92
7.5.1 HIGH PREVALENCE OF ATHEROSCLEROSIS TO DRIVE MARKET 92
TABLE 37 CARDIAC MARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 2021–2028 (USD MILLION) 93
7.6 ISCHEMIA 93
7.6.1 INCREASE IN CARDIAC ISCHEMIA TO BOOST DEMAND FOR CARDIAC MARKER TESTS 93
TABLE 38 CARDIAC MARKER TESTING MARKET FOR ISCHEMIA, BY REGION, 2021–2028 (USD MILLION) 94
8 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE 95
8.1 INTRODUCTION 96
TABLE 39 CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 96
8.2 TROPONIN I AND T 96
8.2.1 HIGH SENSITIVITY AND SPECIFICITY IN DETECTION OF CVD TO DRIVE MARKET 96
TABLE 40 TROPONIN I AND T CARDIAC MARKER TESTING MARKET, BY INDICATION, 2021–2028 (USD MILLION) 97
TABLE 41 TROPONIN I AND T CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 97
TABLE 42 TROPONIN I AND T CARDIAC MARKER TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 98
8.3 CREATINE KINASE-MB 98
8.3.1 POOR SPECIFICITY AND BRIEF ELEVATION DURATION TO HAMPER MARKET GROWTH 98
TABLE 43 CREATINE KINASE-MB CARDIAC MARKER TESTING MARKET, BY INDICATION, 2021–2028 (USD MILLION) 99
TABLE 44 CREATINE KINASE-MB CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 99
TABLE 45 CREATINE KINASE-MB CARDIAC MARKER TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 100
8.4 BRAIN NATRIURETIC PEPTIDE 100
8.4.1 USE OF BNP WITH OTHER CARDIAC MARKERS TO ENHANCE UTILIZATION 100
TABLE 46 CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY INDICATION, 2021–2028 (USD MILLION) 101
TABLE 47 CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY END USER, 2021–2028 (USD MILLION) 101
TABLE 48 CARDIAC MARKER TESTING MARKET FOR BRAIN NATRIURETIC PEPTIDE (BNP AND NT-PROBNP), BY REGION, 2021–2028 (USD MILLION) 102
8.5 MYOGLOBIN 102
8.5.1 USED TO ASSESS PATIENTS WITH CHEST PAIN IN EMERGENCY DEPARTMENT SETTINGS 102
TABLE 49 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY INDICATION, 2021–2028 (USD MILLION) 102
TABLE 50 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY END USER, 2021–2028 (USD MILLION) 103
TABLE 51 CARDIAC MARKER TESTING MARKET FOR MYOGLOBIN, BY REGION, 2021–2028 (USD MILLION) 103
8.6 HIGH-SENSITIVITY C-REACTIVE PROTEIN 103
8.6.1 INCREASING INCIDENCE OF CARDIOVASCULAR DISEASES TO PROPEL ADOPTION 103
TABLE 52 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY INDICATION, 2021–2028 (USD MILLION) 104
TABLE 53 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY END USER, 2021–2028 (USD MILLION) 104
TABLE 54 CARDIAC MARKER TESTING MARKET FOR HIGH-SENSITIVITY C-REACTIVE PROTEIN, BY REGION, 2021–2028 (USD MILLION) 105
8.7 OTHER CARDIAC BIOMARKERS 105
TABLE 55 OTHER CARDIAC BIOMARKERS MARKET, BY INDICATION, 2021–2028 (USD MILLION) 106
TABLE 56 OTHER CARDIAC BIOMARKERS MARKET, BY END USER, 2021–2028 (USD MILLION) 106
TABLE 57 OTHER CARDIAC BIOMARKERS MARKET, BY REGION, 2021–2028 (USD MILLION) 107
9 CARDIAC MARKER TESTING MARKET, BY END USER 108
9.1 INTRODUCTION 109
TABLE 58 CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 109
9.2 LABORATORY TESTING FACILITIES 109
TABLE 59 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 60 CARDIAC MARKER TESTING MARKET FOR LABORATORY TESTING FACILITIES, BY REGION, 2021–2028 (USD MILLION) 110
9.2.1 HOSPITAL LABORATORIES 110
9.2.1.1 Early diagnosis associated with in-house labs to support market growth 110
TABLE 61 CARDIAC MARKER TESTING MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 111
9.2.2 REFERENCE LABORATORIES 111
9.2.2.1 Affordable and time-efficient services associated with reference laboratories to drive market 111
TABLE 62 CARDIAC MARKER TESTING MARKET FOR REFERENCE LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 112
9.2.3 CONTRACT TESTING LABORATORIES 112
9.2.3.1 Ability to perform multiple tests to propel market 112
TABLE 63 CARDIAC MARKER TESTING MARKET FOR CONTRACT TESTING LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 112
9.3 ACADEMIC INSTITUTES 113
9.3.1 CONTINUOUS RESEARCH & DEVELOPMENT OF NOVEL BIOMARKERS TO DRIVE MARKET 113
TABLE 64 CARDIAC MARKER TESTING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 113
9.4 POINT-OF-CARE TESTING FACILITIES 113
9.4.1 EARLY DETECTION AND LOWER TURNAROUND TIME TO PROPEL MARKET 113
TABLE 65 CARDIAC MARKER TESTING MARKET FOR POINT-OF-CARE TESTING FACILITIES, BY REGION, 2021–2028 (USD MILLION) 114
10 CARDIAC MARKER TESTING MARKET, BY REGION 115
10.1 INTRODUCTION 116
TABLE 66 CARDIAC MARKER TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 116
10.2 NORTH AMERICA 117
10.2.1 NORTH AMERICA: RECESSION IMPACT 117
FIGURE 25 NORTH AMERICA: CARDIAC MARKER TESTING MARKET SNAPSHOT 117
TABLE 67 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 68 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 118
TABLE 69 NORTH AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 118
TABLE 70 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 119
TABLE 71 NORTH AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 119
10.2.2 US 120
10.2.2.1 Growing support from NIH for development of novel cardiac biomarkers to drive market 120
TABLE 72 US: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 120
10.2.3 CANADA 120
10.2.3.1 Government initiatives to support market growth 120
TABLE 73 CANADA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 121
10.3 EUROPE 121
10.3.1 EUROPE: RECESSION IMPACT 121
TABLE 74 EUROPE: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 75 EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 122
TABLE 76 EUROPE: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 122
TABLE 77 EUROPE: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 123
TABLE 78 EUROPE: CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 123
10.3.2 GERMANY 123
10.3.2.1 Favorable government policies to support market growth 123
TABLE 79 GERMANY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 124
10.3.3 FRANCE 124
10.3.3.1 Rising geriatric population to drive market 124
TABLE 80 FRANCE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 124
10.3.4 UK 125
10.3.4.1 Government initiatives to boost adoption of cardiac biomarkers 125
TABLE 81 UK: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 125
10.3.5 ITALY 125
10.3.5.1 Adoption of advanced diagnostic technologies to drive market 125
TABLE 82 ITALY: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 126
10.3.6 SPAIN 126
10.3.6.1 Establishment of large and advanced laboratories to drive uptake of cardiac marker testing 126
TABLE 83 SPAIN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 126
10.3.7 REST OF EUROPE 126
TABLE 84 REST OF EUROPE: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 127
10.4 ASIA PACIFIC 127
10.4.1 ASIA PACIFIC: RECESSION IMPACT 127
FIGURE 26 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET SNAPSHOT 128
TABLE 85 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 86 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 129
TABLE 87 ASIA PACIFIC: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 130
TABLE 88 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 130
TABLE 89 ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 131
10.4.2 JAPAN 131
10.4.2.1 Presence of advanced laboratory facilities to drive market 131
TABLE 90 JAPAN: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 131
10.4.3 CHINA 132
10.4.3.1 Growing number of independent clinical laboratories to drive demand for cardiac markers 132
TABLE 91 CHINA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 132
10.4.4 INDIA 132
10.4.4.1 Presence of large patient population to drive demand 132
TABLE 92 INDIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 133
10.4.5 AUSTRALIA 133
10.4.5.1 Increasing healthcare expenditure to support market growth 133
TABLE 93 AUSTRALIA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 133
10.4.6 SOUTH KOREA 134
10.4.6.1 Growing number of private hospitals to drive adoption of advanced testing services 134
TABLE 94 SOUTH KOREA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 134
10.4.7 REST OF ASIA PACIFIC 134
TABLE 95 REST OF ASIA PACIFIC: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 134
10.5 LATIN AMERICA 135
10.5.1 LATIN AMERICA: RECESSION IMPACT 135
TABLE 96 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 97 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 136
TABLE 98 LATIN AMERICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 136
TABLE 99 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 137
TABLE 100 LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 137
10.5.2 BRAZIL 137
10.5.2.1 Increasing government support for advancements in healthcare to support market growth 137
TABLE 101 BRAZIL: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 138
10.5.3 MEXICO 138
10.5.3.1 Rising demand for technologically advanced products to drive uptake of cardiac markers 138
TABLE 102 MEXICO: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 138
10.5.4 REST OF LATIN AMERICA 139
TABLE 103 REST OF LATIN AMERICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 139
10.6 MIDDLE EAST & AFRICA 139
10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO DRIVE DEMAND FOR ADVANCED MARKERS 139
10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 139
TABLE 104 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 140
TABLE 105 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING INSTRUMENTS MARKET, BY TECHNIQUE, 2021–2028 (USD MILLION) 140
TABLE 106 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE, 2021–2028 (USD MILLION) 141
TABLE 107 MIDDLE EAST & AFRICA: CARDIAC MARKER TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 141
10.6.3 GCC COUNTRIES 141
11 COMPETITIVE LANDSCAPE 142
11.1 OVERVIEW 142
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 142
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CARDIAC MARKER TESTING MARKET 143
11.3 REVENUE SHARE ANALYSIS 144
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET, 2018–2022 (USD MILLION) 144
11.4 MARKET RANKING ANALYSIS 145
11.5 COMPANY EVALUATION MATRIX 147
11.5.1 STARS 147
11.5.2 EMERGING LEADERS 147
11.5.3 PERVASIVE PLAYERS 147
11.5.4 PARTICIPANTS 147
FIGURE 29 CARDIAC MARKER TESTING MARKET: COMPANY EVALUATION MATRIX, 2022 148
11.6 STARTUP/SME EVALUATION MATRIX 149
11.6.1 PROGRESSIVE COMPANIES 149
11.6.2 STARTING BLOCKS 149
11.6.3 RESPONSIVE COMPANIES 149
11.6.4 DYNAMIC COMPANIES 149
FIGURE 30 CARDIAC MARKER TESTING MARKET: STARTUP/SME EVALUATION MATRIX, 2022 150
11.7 COMPANY FOOTPRINT 151
TABLE 108 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET 151
TABLE 109 PRODUCT FOOTPRINT ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET 152
TABLE 110 REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN CARDIAC MARKER TESTING MARKET 153
11.8 COMPETITIVE SCENARIOS AND TRENDS 154
TABLE 111 KEY PRODUCT LAUNCHES 154
TABLE 112 KEY DEALS 155
TABLE 113 OTHER KEY DEVELOPMENTS 156
12 COMPANY PROFILES 157
12.1 KEY PLAYERS 157
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 F. HOFFMANN-LA ROCHE AG 157
TABLE 114 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW 157
FIGURE 31 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2022) 158
12.1.2 ABBOTT LABORATORIES 162
TABLE 115 ABBOTT LABORATORIES: COMPANY OVERVIEW 162
FIGURE 32 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 163
12.1.3 SIEMENS HEALTHINEERS AG 166
TABLE 116 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 166
FIGURE 33 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 167
12.1.4 DANAHER CORPORATION 170
TABLE 117 DANAHER CORPORATION: COMPANY OVERVIEW 170
FIGURE 34 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 171
12.1.5 BIO-RAD LABORATORIES, INC. 173
TABLE 118 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 173
FIGURE 35 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 174
12.1.6 BIOMÉRIEUX SA 176
TABLE 119 BIOMÉRIEUX SA: COMPANY OVERVIEW 176
FIGURE 36 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2022) 177
12.1.7 BECTON, DICKINSON AND COMPANY 178
TABLE 120 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 178
FIGURE 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 179
12.1.8 THERMO FISHER SCIENTIFIC INC. 181
TABLE 121 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 181
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 182
12.1.9 DIASORIN S.P.A. 184
TABLE 122 DIASORIN S.P.A.: COMPANY OVERVIEW 184
FIGURE 39 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022) 185
12.1.10 PERKINELMER INC. 187
TABLE 123 PERKINELMER INC.: COMPANY OVERVIEW 187
FIGURE 40 PERKINELMER INC.: COMPANY SNAPSHOT (2022) 188
12.1.11 TOSOH CORPORATION 190
TABLE 124 TOSOH CORPORATION: COMPANY OVERVIEW 190
FIGURE 41 TOSOH CORPORATION: COMPANY SNAPSHOT (2023) 191
12.1.12 LSI MEDIENCE CORPORATION (PHC HOLDINGS CORPORATION) 193
TABLE 125 LSI MEDIENCE CORPORATION: COMPANY OVERVIEW 193
FIGURE 42 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022) 194
12.1.13 QUIDEL CORPORATION 195
TABLE 126 QUIDEL CORPORATION: COMPANY OVERVIEW 195
FIGURE 43 QUIDEL CORPORATION: COMPANY SNAPSHOT (2022) 196
12.1.14 RANDOX LABORATORIES 198
TABLE 127 RANDOX LABORATORIES: COMPANY OVERVIEW 198
12.1.15 GUANGZHOU WONDFO BIOTECH CO., LTD. 200
TABLE 128 GUANGZHOU WONDFO BIOTECH CO., LTD.: BUSINESS OVERVIEW 200
12.1.16 BODITECH MED INC. 202
TABLE 129 BODITECH MED INC.: BUSINESS OVERVIEW 202
12.1.17 TULIP DIAGNOSTICS (P) LTD. 204
TABLE 130 TULIP DIAGNOSTICS (P) LTD.: BUSINESS OVERVIEW 204
12.1.18 BTNX INC. 205
TABLE 131 BTNX INC.: BUSINESS OVERVIEW 205
12.1.19 RESPONSE BIOMEDICAL 207
TABLE 132 RESPONSE BIOMEDICAL: BUSINESS OVERVIEW 207
12.1.20 ALFA SCIENTIFIC DESIGNS, INC. 209
TABLE 133 ALFA SCIENTIFIC DESIGNS, INC.: BUSINESS OVERVIEW 209
12.2 OTHER PLAYERS 210
12.2.1 CTK BIOTECH, INC. 210
12.2.2 CREATIVE DIAGNOSTICS 211
12.2.3 LIFESIGN LLC 211
12.2.4 CARDIOGENICS HOLDINGS INC. 212
12.2.5 ATLAS MEDICAL GMBH 212
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 213
13.1 DISCUSSION GUIDE 213
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 218
13.3 CUSTOMIZATION OPTIONS 220
13.4 RELATED REPORTS 220
13.5 AUTHOR DETAILS 221